An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
Titel:
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
Auteur:
Arkenau, H.-T. Italiano, A. Mak, G. Toulmonde, M. Baird, R.D. Garcia-Corbacho, J. Plummer, R. Flynn, M. Forster, M. Wilson, R.H. Tosi, D. Adenis, A. Donaldson, K. Posner, J. Kawabata, I. Arimura, A. Deva, S. Spicer, J.